Since anti-PD1 antibody applies to various cancers, including gastric cancer, renal cell carcinoma, and Hodgkin lymphoma, measurement of LDH might offer a useful, standard marker for patients treated using ICI. This evidence concerns the gene PDCD1 and cancer.